ノボ・ノルディスクのFDA承認は、第3相ESSENCE試験の結果に基づいており、Wegovyで治療を受けた患者の63%が肝線維症の悪化なしに脂肪性肝炎の改善を達成したのに対し、プラセボでは34%であった。さらに、Wegovyで治療を受けた患者の37% ...

Wegovyは、MASHに対して承認された初のGLP-1ベースの治療薬となる。米国肝臓財団によると、MASHは米国成人の約5%が罹患している。これまで、この疾患に対するFDA承認済みの治療薬は、2024年に承認された Madrigal ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

The Food and Drug Administration (FDA) has granted accelerated approval for Wegovy ® (semaglutide), a glucagon-like peptide-1 receptor agonist, for the treatment of noncirrhotic metabolic ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ: MDGL) stock declined 4% in pre-market trading Monday after the FDA ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...